Communiqués argenx SE

Actions

ARGX

NL0010832176

Marché Fermé - Euronext Bruxelles Autres places de cotation 17:36:27 11/06/2024			Après clotûre 21:59:31
351,7 ^EUR	+0,31 %		350,8	-0,27 %

20:40	Transcript : Argenx SE Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:40 PM
31/05	Derniers écueils avant les baisses de taux ?

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference	04/06	GL
Argenx : argenx Reports First Quarter 2024 Financial Results and Provides Business Update	09/05	PU
Argenx Reports First Quarter 2024 Financial Results and Provides Business Update	09/05	GL
Argenx : argenx announces results of Annual General Meeting of Shareholders	08/05	PU
Argenx announces results of Annual General Meeting of Shareholders	07/05	GL
Argenx : argenx to Present at BofA Securities 2024 Health Care Conference	07/05	PU
Argenx to Present at BofA Securities 2024 Health Care Conference	07/05	GL
Argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024	02/05	GL
Argenx : argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	17/04	PU
Argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	16/04	GL
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey	28/03	AQ
Argenx : argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	27/03	PU
Argenx : argenx Announces Annual General Meeting of Shareholders on May 7, 2024	27/03	PU
Argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	27/03	GL
Argenx Announces Annual General Meeting of Shareholders on May 7, 2024	26/03	GL
Argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia	26/03	GL
Argenx : argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	08/03	PU
Argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	07/03	GL
Argenx : argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update	01/03	PU
Argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update	29/02	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Quand ArgenX tousse, le Bel20 s'enrhume

Le 20 décembre 2023 à 10:26